Pfenex (PFNX) 10-K 15 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 06, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	PFNX
Entity Registrant Name	Pfenex Inc.
Entity Central Index Key	1,478,121
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		23,583,585
Entity Public Float			$ 93.9

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 57,664	$ 81,501
Restricted cash	200
Accounts and unbilled receivables, net	1,306	2,822
Income tax receivable	638	717
Other current assets	1,705	1,878
Total current assets	61,513	86,918
Property and equipment, net	7,397	5,246
Other long term assets	133	80
Intangible assets, net	4,771	5,301
Goodwill	5,577	5,577
Total assets	79,391	103,122
Current liabilities
Accounts payable	1,905	1,284
Accrued liabilities	8,913	9,358
Current portion of deferred revenue	7,421	6,516
Current portion of capital lease obligations	228	54
Total current liabilities	18,467	17,212
Deferred revenue, less current portion	2,742	5,739
Capital lease obligations, less current portion	419	26
Total liabilities	21,628	22,977
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.001, 200,000,000 shares authorized at December 31, 2017 and 2016, respectively, 23,548,280 and 23,429,501 shares issued and outstanding at December 31, 2017 and 2016, respectively	24	24
Additional paid-in capital	219,446	216,144
Accumulated deficit	(161,707)	(136,023)
Total stockholders' equity	57,763	80,145
Total liabilities and stockholders' equity	$ 79,391	$ 103,122

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	200,000,000	200,000,000
Common stock, shares issued	23,548,280	23,429,501
Common stock, outstanding	23,548,280	23,429,501

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 28,780	$ 60,194	$ 9,583
Cost of revenue	5,156	5,313	4,640
Gross profit	23,624	54,881	4,943
Operating expense
Selling, general and administrative	17,674	17,340	14,598
Research and development	31,925	32,418	18,183
Total operating expense	49,599	49,758	32,781
(Loss) income from operations	(25,975)	5,123	(27,838)
Other income, net	119	149	74
Net (loss) income before income taxes	(25,856)	5,272	(27,764)
Income tax benefit (expense)	172	209	(452)
Net (loss) income	$ (25,684)	$ 5,481	$ (28,216)
Net (loss) income per common share, basic and diluted	$ (1.09)	$ 0.23	$ (1.26)
Weighted-average common shares used to compute net (loss) income per share
Basic	23,503	23,389	22,376
Diluted	23,503	23,688	22,376

Consolidated Statements of Chan

Consolidated Statements of Changes Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2014	$ 59,874	$ 21	$ 173,141	$ (113,288)
Beginning Balance, Shares at Dec. 31, 2014		20,405
Exercise of stock options	201		201
Exercise of stock options, shares		277
Issuance of common stock under employee stock purchase plan	140		140
Issuance of common stock under employee stock purchase plan, shares		24
Stock-based compensation expense	1,840		1,840
Issuance of common stock, net of discount	38,028	$ 3	38,025
Issuance of common stock, net of discount, shares		2,610
Offering costs	(686)		(686)
Net income (loss)	(28,216)			(28,216)
Ending Balance at Dec. 31, 2015	71,181	$ 24	212,661	(141,504)
Ending Balance, Shares at Dec. 31, 2015		23,316
Exercise of stock options	123		123
Exercise of stock options, shares		78
Issuance of common stock under employee stock purchase plan	204		204
Issuance of common stock under employee stock purchase plan, shares		36
Stock-based compensation expense	3,156		3,156
Net income (loss)	5,481			5,481
Ending Balance at Dec. 31, 2016	80,145	$ 24	216,144	(136,023)
Ending Balance, Shares at Dec. 31, 2016		23,430
Exercise of stock options	$ 26		26
Exercise of stock options, shares	85	85
Issuance of common stock under employee stock purchase plan	$ 153		153
Issuance of common stock under employee stock purchase plan, shares		33
Stock-based compensation expense	3,123		3,123
Net income (loss)	(25,684)			(25,684)
Ending Balance at Dec. 31, 2017	$ 57,763	$ 24	$ 219,446	$ (161,707)
Ending Balance, Shares at Dec. 31, 2017		23,548

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net (loss) income	$ (25,684)	$ 5,481	$ (28,216)
Adjustments to reconcile net (loss) income to net cash Provided by (used in)operating activities
Depreciation and amortization	876	670	541
Amortization of intangible assets	530	531	531
Deferred income taxes		1,955	(1,955)
Stock-based compensation expense	3,123	3,156	1,840
(Gain)/Loss on disposal of property and equipment	(20)	250	59
Changes in operating assets and liabilities
Accounts and unbilled receivables	1,516	(139)	(1,099)
Other current assets	173	(160)	58
Other long term assets	(53)	25	(68)
Accounts payable	628	431	(243)
Accrued liabilities	(585)	3,250	3,318
Deferred revenue	(2,092)	(35,840)	47,894
Income tax receivable	78	(1,884)	1,570
Net cash (used in) provided by operating activities	(21,510)	(22,274)	24,230
Cash flows from investing activities
Acquisitions of property and equipment	(2,242)	(2,868)	(1,470)
Proceeds from sales of equipment	45	8
Net cash used in investing activities	(2,197)	(2,860)	(1,470)
Cash flows from financing activities
Repayments of borrowings under line of credit agreement		(3,813)
Restricted cash	(200)	3,959	(4)
Repayments of capital lease obligations	(109)
Proceeds from exercise of stock options and other stock issuances	179	327	342
Proceeds from issuance of common shares from secondary offering			37,342
Net cash (used in) provided by financing activities	(130)	473	37,680
Net (decrease) increase in cash and cash equivalents	(23,837)	(24,661)	60,440
Cash and cash equivalents
Beginning of year	81,501	106,162	45,722
End of year	57,664	81,501	106,162
Supplemental schedule of cash flow information
Cash paid for interest	22	30	104
Cash paid for taxes		32	942
Non-cash financing and investing transactions
Capital lease obligation	676	42	$ 89
Purchases of property and equipment included in accounts payable and accrued liabilities	$ 361	$ 248

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Business Activities and Organization Pfenex Inc. (the Company or Pfenex) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology ® ® ® ® PF708 is a therapeutic equivalent candidate to Forteo, marketed by Eli Lilly and Company. The Company completed enrollment in its Study PF708-301 mid-February Top-line The Company is also developing Px563L/RPA563, novel anthrax vaccine candidates, in response to the United States government’s unmet demand for increased quantity, stability and dose-sparing regimens of anthrax vaccine . In July 2016, Pfenex and Jazz announced an agreement under which Pfenex granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. In addition to the Company’s lead product candidates, its pipeline includes various other biosimilar candidates, including PF582, the Company’s biosimilar candidate to Lucentis ® ® The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. Subsidiary—Pfenex India Development Private Limited (“Pfenex India”) In July 2016, to assist with the continued research and development of its pipeline products, the Company formed a new entity in India. An application for incorporation with the Government of India Ministry of Corporate Affairs was filed and approved for the Company’s subsidiary, Pfenex India Development Private Limited. There has been limited activity in the subsidiary, and all intercompany transactions have been eliminated in the consolidated financial statements. In early 2018, this subsidiary was legally dissolved. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), and reflect all of the Company’s activities, including those of its wholly-owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These adjustments consist of normal and recurring accruals, as well as non-recurring Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. During 2017, 2016 and 2015, substantially all of the Company’s long-lived assets were located within the United States. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates. Risk and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s products if approved for sale, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals. Products developed by the Company require clearances from international and domestic regulatory agencies prior to commercial sales in such jurisdictions. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. As of December 31, 2017, the Company had an accumulated deficit of $161.7 million and expects to incur substantial operating losses for the next several years. Although the Company believes it has sufficient cash resources to fund all necessary activities leading up to and including submission of an NDA for PF708 to the FDA, the Company may need to obtain additional financing in order to complete clinical studies, launch and commercialize any product candidates for which the Company receives regulatory approval. If Pfenex is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. Cash and Cash Equivalents The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of six months or less at the time of purchase to be cash equivalents. Cash amounts that are restricted as to withdrawal or usage are presented as restricted cash. In January 2017, the Company entered into a Borrower’s Pledge Agreement with U.S. Bank which required $0.2 million in restricted cash to be provided as security for the Company’s commercial credit card arrangement with this bank. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at three major financial institutions as of December 31, 2017. For the Company’s cash position of $57.9 million as of December 31, 2017, which included restricted cash of $0.2 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance non-performance. Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2017 and 2016, receivables were concentrated among three customers representing 89% of total net receivables for both years. The Company recorded an allowance for doubtful accounts of $0.1 million at December 31, 2016. No allowance for doubtful accounts was recorded at December 31, 2017. For the year ended December 31, 2017, revenue was concentrated among two customers and/or collaboration partners representing 94% of total revenues. Revenue from one collaboration partner represented 80% of total revenue for the year ended December 31, 2016. Two customers and/or collaboration partners represented 70% of total revenue for the year ended December 31, 2015. A portion of revenue is earned from sales outside the United States. Non-U.S. non-U.S. Years Ended December 31, 2017 2016 2015 (in thousands) US Revenue $ 6,477 $ 54,641 $ 8,399 Non-US 22,303 5,553 1,184 $ 28,780 $ 60,194 $ 9,583 During the year ended December 31, 2017, Ireland accounted for more than 10% of the Company’s revenue. For the years ended December 31, 2016 and 2015, no single foreign country accounted for more than 10% of the Company’s revenues. Fair Value of Financial Instruments Financial instruments, including cash, cash equivalents, restricted cash and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: • Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at December 31, 2017 and December 31, 2016 included the Company’s cash and cash equivalents. There were no Level 1 liabilities; • Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at December 31, 2017 or December 31, 2016; and • Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at December 31, 2017 or December 31, 2016. Accounts and Unbilled Receivables Accounts receivable represent primarily commercial receivables associated with the Company’s service fees, license fees, product sales and receivables from U.S. government contracts. Accounts receivable amounted to $1.1 million and $1.9 million as of December 31, 2017 and 2016, respectively. Unbilled receivables represent reimbursable costs in excess of billings and, where applicable, accrued profit related to long-term government contracts for which revenue has been recognized, but the customer has not yet been billed. Unbilled receivables amounted to $0.2 million and $1.0 million as of December 31, 2017 and 2016, respectively. The Company evaluates the collectability of its receivables based on a variety of factors, including the length of time the receivables are past due, the financial health of its customers and historical experience. Based upon the review of these factors, the Company recorded no allowance for doubtful accounts at December 31, 2017 and $0.1 million at December 31, 2016. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from five to ten years with the exception of leasehold improvements which are amortized over the shorter of the lease term or their estimated useful life. Intangible Assets Intangible assets include customer relationships, developed technology and trade names related to the Company’s asset acquisition and have been capitalized and amortized over the estimated useful life of 15 years, 20 years and 15 years, respectively. Impairment of Long-Lived Assets Other Than Goodwill The Company assesses potential impairments to its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flow expected to result from the use of the assets. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset. No impairment was noted as of the years ended December 31, 2017 or 2016. Goodwill Goodwill is the excess of purchase price over the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed, in a business combination. The Company does not amortize goodwill. Instead, goodwill is tested for impairment annually and between annual tests if the Company becomes aware of an event or a change in circumstances that would indicate the carrying amount may be impaired. The Company performs its annual impairment testing as of December 31 st two-step Preclinical and Clinical Trial Accruals The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on the Company’s behalf. The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of series or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses until the services are rendered. Revenue The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, license agreements, government contracts and sales of reagent protein products, which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 6—Significant Research and Development Agreements. The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case Upfront, nonrefundable licensing payments are assessed to determine whether or not the licensee is able to obtain standalone value from the license. Where the license does not have standalone value, non-refundable Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed. Revenue under service agreements are recorded as services are performed. These agreements do not require development achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement. The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. For the year ended December 31, 2017, revenue was recognized in connection with the achievement of development milestones associated with the Jazz collaboration. The Company recognized $1.0 million and $0.8 million in connection with the achievement of certain milestones for the years ended December 31, 2017 and 2016, respectively. The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of December 31, 2017 and 2016, the Company has had minimal product returns related to reagent protein product sales. No reserve for warranty and return rights was recorded as of December 31, 2017 and 2016. Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user Cost of Revenue Cost of revenue includes costs incurred in connection with the execution of service contracts. These are primarily reimbursable costs under the Company’s government contracts and include costs for third-party manufacturing, materials and internal labor. Costs related to government contract activities are generally recognized as incurred. Cost of revenue also includes costs to manufacture or purchase, package and ship the Company’s reagent products; these costs are recognized upon shipment to the customer. Research and Development Expenses Research and development expenses are recognized as incurred and amounted to $31.9 million, $32.4 million and $18.2 million for the years ending December 31, 2017, 2016 and 2015, respectively. Stock-Based Compensation Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of estimated forfeitures, over the requisite service period. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. The Company estimates the fair value of stock options and other equity-based compensation using a Black-Scholes option pricing model on the date of grant. The Black-Scholes valuation model requires multiple subjective inputs, which are discussed further in Note 8 — Stock-Based Compensation. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally four years; however, certain provisions in the Company’s equity compensation plan provides for shorter and longer vesting periods under certain circumstances. Comprehensive Income (Loss) Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner Income Taxes The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future tax benefit, if any, to be derived from tax credits and loss carryforwards. Deferred income tax expense or benefit would represent the net change during the year in the deferred income tax asset or liability. Deferred tax assets, if any, are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Net (Loss) Income per Share of Common Stock Basic net (loss) income per common share is calculated by dividing the net (loss) income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding and potentially dilutive securities during the period under the treasury stock method. For purposes of the diluted net (loss) income per share calculation, stock options and employee purchase plan shares are considered to be potentially dilutive securities. Securities are excluded from the computation of diluted net (loss) income per share if their effect would be anti-dilutive to earnings per share. Because the Company has reported a net loss for the years ended December 31, 2017 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. There were no accumulated dividends related to preferred stock at December 31, 2017, 2016 or 2015. Immediately prior to the IPO, the Company issued shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09 In February 2016, the FASB issued ASU No. 2016-02 In November 2016, the FASB issued ASU 2016-18, beginning-of-period end-of-period beginning-of-period end-of-period In January 2017, the FASB issued ASU No. 2017-04, two-step In May 2017, the FASB issued ASU 2017-09, 2017-09

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. Fair Value Measurements The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of December 31, 2017 and 2016, were determined using the inputs described above and are as follows: Total Fair Value Measurements at Reporting Quoted Prices Significant Significant (in thousands) December 31, 2017 Cash and money market funds $ 57,864 $ 57,864 $ — $ — Total assets measured at fair value $ 57,864 $ 57,864 $ — $ — December 31, 2016 Cash and money market funds $ 81,501 $ 81,501 $ — $ — Total assets measured at fair value $ 81,501 $ 81,501 $ — $ — Cash and money market funds at December 31, 2017 include restricted cash, which is included in current assets on the balance sheet. The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no significant transfers into or out of Level 1, 2, or 3 during the periods presented.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment Property and equipment consisted of the following: December 31, 2017 2016 (in thousands) Furniture and equipment $ 355 $ 350 Computers and IT equipment 368 290 Purchased software 931 869 Lab and research equipment 8,131 5,022 Leasehold improvements 865 739 Construction-in-progress 162 575 Other fixed assets 64 64 Total property and equipment, gross 10,876 7,909 Less: accumulated depreciation and amortization (3,479 ) (2,663 ) Property and equipment, net $ 7,397 $ 5,246 Total property and equipment assets under capital lease were $1.1 million and $0.2 million as of December 31, 2017 and 2016. Accumulated depreciation related to assets under capital lease as of these dates were $94 thousand and $40 thousand, respectively. For the years ended December 31, 2017, 2016 and 2015, total depreciation and amortization expense was $0.9 million, $0.7 million and $0.5 million, respectively, and is included in selling, general and administrative expenses and research and development in the accompanying consolidated statements of operations as follows: Years ended December 31, 2017 2016 2015 (in thousands) Selling, general and administrative $ 327 $ 254 $ 267 Research and development 549 416 274 Total depreciation and amortization expense $ 876 $ 670 $ 541

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets Intangible assets consisted of the following: December 31, 2017 2016 (in thousands) Customer relationships $ 3,750 $ 3,750 Developed technology 4,400 4,400 Trade names 910 910 Gross intangible assets 9,060 9,060 Less: Accumulated amortization (4,289 ) (3,759 ) Total intangible assets, net $ 4,771 $ 5,301 Amortization expense related to intangible assets was $0.5 million for each of the years ended December 31, 2017, 2016 and 2015. Amortization expense is included within selling, general and administrative expense in the accompanying consolidated statements of operations. As of December 31, 2017, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued liabilities consisted of the following: December 31, 2017 2016 (in thousands) Accrued vacation $ 477 $ 553 Deferred rent 620 627 Accrued bonuses 1,672 1,385 Other accrued employee-related liabilities 462 293 Accrued professional fees 575 266 Accrued supplier liability 690 428 Accrued subcontractor costs 2,681 4,901 Accrued clinical trial costs 866 73 Other accrued liabilities 870 832 Total accrued liabilities $ 8,913 $ 9,358

Significant Research and Develo

Significant Research and Development Agreements	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
Significant Research and Development Agreements	6. Significant Research and Development Agreements The Company has two types of research and development agreements (i) those for which the Company co-develops Collaboration and License Agreements Jazz In July 2016, the Company entered into a development and license agreement with Jazz Pharmaceuticals for the development and commercialization of multiple early stage hematology/oncology product candidates, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, and in the third quarter of 2017, achieved a process development milestone. The agreement also includes an option for Jazz to negotiate a license for a recombinant pegaspargase product candidate with the Company. Under the agreement, Pfenex received an upfront and option payment totaling $15.0 million in July 2016 and may be eligible to receive additional payments based on achievement of certain research and development, regulatory and sales-related milestones. In December 2017, the Company and Jazz entered into an amended and restated agreement. In connection with the amendment and restatement of the Jazz Agreement (as amended, the Amended Jazz Agreement), Pfenex received a total of $18.5 million, consisting of an upfront payment of $5.0 million and a payment of $13.5 million for development achievement. Pfenex may be eligible to receive additional payments under the Amended Jazz Agreement of up to $189.3 million based on achievement of certain research and development, regulatory and sales-related milestones. The total milestones are categorized as follows: $30.3 million based on achievement of certain research and development milestones; $34.0 million for certain regulatory milestones; and $125.0 million for sales milestones. For the non-sales-related non-sales-related product-by-product In accordance with ASC 605-25, The upfront and option payment for the original Jazz agreement and the amendment are being deferred and will be recognized as revenue ratably over the period in which the Company expects services to be rendered for each respective unit of accounting. As previously disclosed, the estimated period of revenue recognition approximates a range of 15 to 32 months. Based on changes to this estimate that occurred during the quarter ended June 30, 2017, the Company has modified the period of revenue recognition to range from 15 to 35 months. During the year ended December 31, 2017, the Company completed the service period related to one of the hematology products. During the years ended December 31, 2017 and 2016, the Company recorded revenue of approximately $21.6 million and $3.6 million related to the Jazz Collaboration, respectively. As of December 31, 2017 and 2016, deferred revenue associated with the Jazz collaboration was $10.1 million and $12.1 million, respectively. This deferred revenue will be recognized over the period of performance from 15 to 18 months, subsequent to December 31, 2017. Pfizer In February 2015, the Company entered into a development and license agreement with Pfizer (Pfizer Agreement) for the development and commercialization of PF582. Under the terms of the Pfizer Agreement, in March of 2015 the Company received a non-refundable Funding Agreements The U.S. Department of Health and Human Services In July 2010, the Company entered into a contract with BARDA within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services to develop a production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. The arrangement is a cost plus fixed fee contract comprised of a base program and follow on options at BARDA’s election. At the inception of the contract, both BARDA and the Company entered into the arrangement with the expectation that BARDA would fund all costs of development and no costs in excess of the arrangement would be incurred by the Company. In December 2014, the Company filed the investigational new drug (IND) application for Px563L. BARDA extended the contract in December 2014 and provided additional funding, increasing the total contract to $25.2 million. The development contract was completed in August 2015. In August 2015, the Company entered into a contract with BARDA for the advanced development of Px563L/RPA563 as a novel vaccine candidate for the prevention of anthrax infection (BARDA Advanced Development Agreement). The BARDA Advanced Development Agreement is a cost plus fixed fee development contract valued at up to approximately $143.5 million, including a 30 month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. In addition to the base period, BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L/RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019. Over the course of 2017, the Company continued to collect favorable stability data for both products. Potential next milestones in 2018 are the triggering of analytical and non-clinical Revenue is recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under the BARDA contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The Company recorded revenues of $5.5 million, $5.0 million and $3.7 million for services performed in the years ended December 31, 2017, 2016 and 2015, respectively. Reimbursable costs related to fulfilling on this contract amounted to $3.5 million, $3.9 million and $2.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are reflected in cost of revenue in the accompanying consolidated statements of operations. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Any such overage is expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 52.242-15 The National Institute of Allergy and Infectious Diseases In September 2012, the Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID) to provide services to advance vaccine components and technologies that accelerate the immune response for use in post-event settings following the intentional release of the NIAID Category A Priority Pathogen Bacillus anthracis or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A Priority Pathogen B. anthracis. The arrangement was a cost plus fixed fee contract comprised of a base program and 13 follow-on Revenue was recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily included direct labor, subcontracts and indirect costs. In addition, the Company received a fixed fee under the NIAID contract, which was unconditionally earned as allowable costs were incurred and was not contingent on success factors. Reimbursable costs under this NIAID contract, including the fixed fee, were generally recognized as revenue in the period the reimbursable costs were incurred and became billable. The Company recorded revenues of $0.3 million, $0.5 million and $0.9 million for services performed in the years ended December 31, 2017, 2016 and 2015, respectively. Reimbursable costs related to fulfilling this contract amounted to $0.3 million, $0.4 million and $0.5 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are reflected in cost of revenues in the accompanying consolidated statements of operations. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Such overage was expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. Strides Arcolab Limited In March 2013, the Company and Strides Arcolab entered into a joint venture agreement (JVA) to provide a vehicle for the advancement of certain biosimilars. In August of 2017, the Company and Strides Arcolab entered into a termination agreement pursuant to which the JVA was terminated. There had been no activity under the JVA.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Lease Agreements In June 2010, the Company entered into an operating lease agreement (Lease) with a landlord for an initial term of 10 years, for its corporate headquarters comprised of one building located in San Diego, California. Occupation of the premises under the Lease began in April 2011. Under the terms of the Lease, the Company pays annual base rent, subject to an annual fixed percentage increase, plus its share of common operating expenses and tax obligations. The annual base rent was subject to abatement of 50% for the first year of the Lease. The Company recognizes rent expense on a straight-line basis over the lease term. In September 2014, the Company amended the Lease to extend the term for an additional three years through March 31, 2024 and to an additional 7,315 square feet of leased space. The extended term on the existing space increased total estimated rent payments by approximately $1.4 million. Base rent payments for the new space commenced in December 2014 and increased total estimated rent payments over the life of the Lease by approximately $1.5 million. In November 2015, the Company further amended the Lease to add facilities consisting of 16,811 square feet. Base rent payments for the new space commenced in March 2016 and June 2016 and increased total estimated rent payments over the life of the Lease by approximately $2.3 million. In January 2017, a sublease agreement was executed with a tenant to lease a portion of leased space from the Company for eight months. The amounts received are offset against rent expense. Rent expense was $0.7 million, $0.7 million, and $0.5 million for the years ended December 31, 2017, 2016 and 2015, respectively, which is included in selling, general and administrative and research and development expenses in the accompanying consolidated statements of operations as follows: Years Ended December 31, 2017 2016 2015 (in thousands) Selling, general and administrative $ 407 $ 375 $ 290 Research and development 326 364 248 Total rent expense $ 733 $ 739 $ 538 In addition to the Lease, the Company has entered into operating and capital lease agreements for office and lab equipment that expire at various dates through December 2021. As of December 31, 2017, the total estimated future annual minimum lease payment obligations under the Company’s non-cancelable Payment Amounts Operating Capital Total (in thousands) 2018 $ 984 $ 260 $ 1,244 2019 884 260 1,144 2020 891 199 1,090 2021 908 1 909 2022 and thereafter 2,140 — 2,140 Total future minimum lease payments $ 5,807 $ 720 $ 6,527 Clinical Study and Development Activity Commitments The Company has entered into agreements with contract research organizations and subcontractors to further develop its product candidates. The total contracted costs under these arrangements totaled approximately $25.9 million as of December 31, 2017, of which $15.9 million has been incurred to date. These contracts can be cancelled at any time, with some having certain cancellation fees associated with the termination of the contract, and others that only obligate the Company through the termination date. Contingencies From time to time, the Company may be involved in legal proceedings, claims, and litigation in the ordinary course of business. At December 31, 2017 and 2016 there were no material legal proceedings.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation Summary Stock-Based Compensation Information The following table summarizes stock-based compensation expense: Years Ended December 31, 2017 2016 2015 (in thousands) Cost of revenues $ 265 $ 225 $ 124 Research and development 1,028 822 371 Selling, general and administrative 1,830 2,109 1,345 Total $ 3,123 $ 3,156 $ 1,840 2017 2016 2015 (in thousands) Stock-based compensation from: Stock options $ 2,993 $ 2,983 $ 1,761 Employee stock purchase plan 130 173 79 Total $ 3,123 $ 3,156 $ 1,840 Stock Option Plan The Company’s board of directors adopted, and the Company’s stockholders approved, the Company’s 2009 Equity Incentive Plan (2009 Plan) in 2009. The 2009 Plan terminated in connection with the Company’s IPO in 2014 and, accordingly, no awards will be granted under the 2009 Plan following the IPO. However, the 2009 Plan will continue to govern outstanding awards granted thereunder. An aggregate of 1.1 million shares of common stock was reserved for issuance under the 2009 Plan. The 2009 Plan provided for the grant of incentive stock options and for the grant of nonstatutory stock options, restricted stock, restricted stock units, and stock appreciation rights to the Company’s employees, directors and consultants. As of December 31, 2017, awards covering 0.4 million shares of common stock were outstanding under the 2009 Plan. In July 2014, the board of directors adopted a 2014 Equity Incentive Plan (2014 Plan) and the Company’s stockholders approved it. In May 2017, the Company’s stockholders approved an amendment to the 2014 Equity Incentive Plan (2014 Amended Plan), to, among other things, increase the available shares by 2.5 million. The 2014 Amended Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants and parent and subsidiary corporations’ employees and consultants. The shares available for issuance under the 2014 Amended Plan include shares returned to the 2009 Plan as the result of expiration or termination of awards (provided that the maximum number of shares that may be added to the 2014 Amended Plan pursuant to such previously granted awards under the 2009 Plan is 961,755 shares). The maximum number of shares that may be issued under the 2014 Amended Plan is 5.5 million plus shares added from 2009 Plan, if any. As of December 31, 2017, a total of 3.1 million shares of common stock were available for issuance pursuant to the 2014 Amended Plan. As of December 31, 2017, awards covering 2.4 million shares of common stock were outstanding under the 2014 Amended Plan. In September 2016, the board of directors adopted the 2016 Inducement Equity Incentive Plan (2016 Plan). The 2016 Plan provides for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to new employees. Stock options granted under the 2016 Plan have a term of ten years from the date of grant, the exercise price for the shares to be issued will be no less than 100% of the fair market value per share on the date of grant and generally vest over a four-year period. The maximum aggregate number of shares that may be issued under the 2016 Plan is 500,000 shares. As of December 31, 2017, a total of 0.1 million shares of common stock were available for issuance pursuant to the 2016 Plan. As of December 31, 2017, awards covering 0.4 million shares of common stock were outstanding under the 2016 Plan. Stock options granted to date under the 2009 Plan and the 2014 Plan have a term of ten years from the date of grant, and generally vest over a four-year period. However, in the event that an incentive stock option (ISO) granted to a participant who, at the time the ISO is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, the term of the ISO shall be five years from the grant date or such shorter term as may be provided in the award agreement. In July 2014, the board of directors adopted the 2014 Employee Stock Purchase Plan (ESPP) and the stockholders approved it. As of December 31, 2017, a total of 1,270,388 shares of common stock were available for issuance under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of: (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator. As of December 31, 2017, 92,493 shares have been purchased under the ESPP. Stock Options The exercise price of all options granted during the years ended December 31, 2017, 2016 and 2015 was equal to the estimated fair value of the underlying common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The following assumptions were used to estimate the fair value of stock options: Years Ended December 31, 2017 2016 2015 Risk-free interest rate 1.5 – 2.4% 1.1 – 2.0% 1.3 – 1.9% Expected volatility 64.0 – 68.0% 63.1 – 68.6% 49.8 – 68.2% Expected dividend yield 0.0% 0.0% 0.0% Expected life of options in years 2.2 - 9.3 5.1 - 6.3 6.0 The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model requires multiple subjective inputs, including a measure of expected future volatility. Prior to the Company’s IPO, the Company’s stock did not have a readily available market. Consequently, the expected future volatility was based on the historical volatility for comparable publically traded companies over the most recent period commensurate with the estimated expected term of the Company’s stock options. Beginning in the fourth quarter of 2016, the expected future volatility was based on the historical volatility for the Company’s common stock. Following the completion of the Company’s IPO in July 2014, the fair value of options granted is based on the closing price of the Company’s common stock on the date of grant as quoted on the NYSE American. The risk-free interest rate assumption is based upon observed interest rates during the period appropriate for the expected term of the options. The expected term of the options has been estimated using the simplified method to determine the expected life of the Company’s options due to insufficient activity as a basis from which to estimate future exercise patterns. With the exception of 1,217,784 shares of common stock issued in connection with the payment of all accrued and unpaid dividends on the preferred stock immediately prior to the completion of the Company’s IPO, the Company had never declared or paid dividends and has no plans to do so in the foreseeable future. Accordingly, the dividend yield assumption is based on the expectation that the Company will not pay dividends on its common stock in the future. Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The weighted-average grant date fair value of options granted during the year ended December 31, 2017, 2016 and 2015 was $2.92, $5.47 and $5.91 respectively. Total fair value of shares vested during the years ended December 31, 2017, 2016 and 2015 was $3.9 million, $972 thousand and $971 thousand, respectively. Stock option transactions under the 2009, 2014 and 2016 Plans during the year ended December 31, 2017 were as follows: Number of Weighted Weighted Aggregate Outstanding at January 1, 2017 2,571 $ 8.62 Granted 1,583 6.51 Exercised (85 ) 0.31 Cancelled (forfeited) (832 ) 9.81 Outstanding at December 31, 2017 3,237 $ 7.50 7.40 $ 392 Vested and expected to vest at December 31, 2017 2,921 $ 7.64 7.21 $ 392 Vested and exercisable at December 31, 2017 1,512 $ 8.44 5.91 $ 392 The Company received $26 thousand, $123 thousand and $201 thousand for the years ended December 31, 2017, 2016 and 2015, respectively, for options exercised. As of December 31, 2017, there was approximately $4.3 million of unrecognized compensation cost related to unvested stock option awards, and the weighted-average period over which this cost is expected to be recognized is 2.54 years. The total aggregate intrinsic value, which is the amount, if any, by which the exercise price was exceeded by the estimated fair value of the Company’s common stock, of options exercised, was $0.3 million, $0.6 million and $4.7 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Retirement Plan	9. Retirement Plan The Company has a 401(k) Savings Plan (401(k)). The 401(k) is for the benefit of all qualifying employees and permits voluntary contributions by employees up to a maximum percentage allowable by current IRS regulations. During the years ended December 31, 2017 and 2016, the Company made matching contributions to the 401(k) of $226 thousand and $197 thousand, respectively. During the year ended December 31, 2015, the Company did not match employee contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The components of the income tax (benefit) expense are as follows: Years Ended December 31, 2017 2016 2015 (in thousands) Current $ (172 ) $ (2,164 ) $ (680 ) Deferred — 1,955 1,132 Total (benefit) expense $ (172 ) $ (209 ) $ 452 On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. Pursuant to the SEC Staff Accounting Bulletin (“SAB”) No. 118, “Income Tax Accounting Implications of the Tax Cuts and Jobs Act” (“SAB 118”), a company may select between one of three scenarios to determine a reasonable estimate arising from the Tax Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate as the law is still being analyzed. The Company was able to provide a reasonable estimate for the revaluation of deferred taxes by recording a net tax provision of $6.4 million in the period ending December 31, 2017 which is offset by a full valuation allowance. This tax expense is primarily due to the corporate rate reduction. The Company has also recorded a tax benefit of $0.2 million for the AMT credits which are refundable in tax year 2018 through 2022. As of December 31, 2017, the Company had federal and state research and development credits carryforwards of approximately $4.1 million and $2.7 million, respectively, to offset potential tax liabilities. The federal research and development credits have a 20-year The Company completed an IRC Section 382/383 analysis through December 31, 2014. The Company has not updated such Section 382 study through December 31, 2017. Future and current utilization of federal and state tax attribute carry-forwards may be limited, if, upon completion of our Section 382 study through December 31, 2017, it determines ownership changes within the meaning of Section 382 have occurred. Significant components of the Company’s deferred tax assets as of December 31, 2017 and 2016 are shown below. A valuation allowance of $19.2 million and $14.5 million for the years ended December 31, 2017 and 2016, respectively, has been established to offset deferred tax assets as realization of such assets is uncertain. December 31, 2017 2016 (in thousands) Deferred tax assets Net operating losses $ 10,968 $ 7,442 Stock-based compensation 1,196 1,069 Research and development credits 5,473 3,456 Deferred revenue 2,581 4,166 Accruals and other 696 846 Total deferred tax assets 20,914 16,979 Deferred tax liabilities Depreciation and amortization (436 ) (629 ) Intangible assets (1,267 ) (1,867 ) Total deferred tax liabilities (1,703 ) (2,496 ) Valuation allowance (19,211 ) (14,483 ) Net deferred tax asset $ — $ — A reconciliation of the Company’s effective tax rate and federal statutory tax rate at December 31, 2017, 2016 and 2015 is as follows: December 31, 2017 2016 2015 (in thousands) Federal income taxes $ (8,791 ) $ 1,792 $ (9,440 ) State income taxes (949 ) 190 (673 ) State rate changes (392 ) (1,080 ) 743 Impact of change in federal income tax rates 6,401 — — Stock-based compensation 623 489 (117 ) Valuation allowance 4,728 130 9,984 Research and development credits (1,897 ) (1,683 ) (815 ) Permanent items and other 105 (47 ) 770 Total income tax (benefit) expense $ (172 ) $ (209 ) $ 452 In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not Following is a tabular reconciliation of the Company’s Unrecognized Tax Benefits activity (excluding interest and penalties): December 31, 2017 2016 2015 (in thousands) Beginning balance of unrecognized tax benefits $ 730 $ 301 $ — Additions based on tax positions related to the current year 361 369 162 Additions based on tax positions of prior years — 79 139 Reductions for tax positions of prior years (59 ) (19 ) — Ending balance of unrecognized tax benefits $ 1,032 $ 730 $ 301 As of December 31, 2017, if recognized, approximately $0.9 million would affect the effective tax rate if the Company did not have a full valuation allowance. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. No accrued interest or penalties were included in its consolidated balance sheets at December 31, 2017, or 2016, and the Company did not recognize any interest and/or penalties in its consolidated statements of operations during the years ended December 31, 2017, 2016, or 2015. The Company does not anticipate significant increases or decreases within the next 12 months with respect to its unrecognized tax benefit. The Company is subject to income tax in the United States and California. The Company currently is under examination by the IRS for tax years December 31, 2015 and December 31, 2016. The Company’s tax years 2013 and forward are subject to examination by the United States tax authorities and tax years 2009 and forward are subject to examination by California and various state tax authorities.

Net (Loss) Income Per Share of

Net (Loss) Income Per Share of Common Stock	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Net (Loss) Income Per Share of Common Stock	11. Net (Loss) Income Per Share of Common Stock The following table summarizes the computation of basic and diluted net (loss) income per share attributable to common stockholders of the Company: December 31, 2017 2016 2015 (in thousands, except per share data) Net (loss) income $ (25,684 ) $ 5,481 $ (28,216 ) Weighted average shares used to compute basic net (loss) income per share 23,503 23,389 22,376 Dilutive effect of employee stock option plans — 299 — Dilutive weighted-average common shares outstanding 23,503 23,688 22,376 Basic and diluted net (loss) income per common share $ (1.09 ) $ 0.23 $ (1.26 ) Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding for the period. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method, if inclusion of these is dilutive. Because the Company reported a net loss for the years ended December 31, 2017 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding because of their anti-dilutive impact to earnings per share: December 31, 2017 2016 2015 (in thousands) Options to purchase common stock 3,237 1,774 1,638 ESPP 75 60 33

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	[12. Subsequent Events]

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	13. Quarterly Financial Data (unaudited) The following is a summary of the quarterly results of the Company for the years ended December 31, 2017 and 2016: First Second Third Fourth Year Ended (in thousands, except for per share data) 2017 Revenues $ 2,818 $ 3,029 $ 5,024 $ 17,909 $ 28,780 Cost of revenues 810 905 1,766 1,675 5,156 Gross profit 2,008 2,124 3,258 16,234 23,624 Operating expenses 12,084 14,486 12,111 10,918 49,599 Other income, net 44 38 35 2 119 Income tax benefit — — — 172 172 Net (loss) income (10,032 ) (12,324 ) (8,818 ) 5,490 (25,684 ) Net (loss) income per share, basic and diluted $ (0.43 ) $ (0.52 ) $ (0.37 ) $ 0.23 $ (1.09 ) Shares used in the calculation of net (loss) income per share: Basic 23,436 23,486 23,539 23,548 23,503 Diluted 23,436 23,486 23,539 23,697 23,503 2016 Revenues $ 2,764 $ 3,135 $ 48,824 $ 5,471 $ 60,194 Cost of revenues 1,276 1,440 1,285 1,312 5,313 Gross profit 1,488 1,695 47,539 4,159 54,881 Operating expenses 9,696 11,907 13,095 15,060 49,758 Other income, net — 46 52 51 149 Income tax benefit (expense) (1 ) — — 210 209 Net income (loss) (8,209 ) (10,166 ) 34,496 (10,640 ) 5,481 Net income (loss) per share: Basic $ (0.35 ) $ (0.43 ) $ 1.47 $ (0.45 ) $ 0.23 Diluted $ (0.35 ) $ (0.43 ) $ 1.46 $ (0.45 ) $ 0.23 Shares used in the calculation of net income (loss) per share: Basic 23,353 23,379 23,400 23,424 23,389 Diluted 23,353 23,379 23,689 23,424 23,688

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS Years Ended December 31, 2017 2016 2015 (in thousands) Allowance for Doubtful Accounts: Beginning balance $ 50 $ 408 $ 585 Charged to costs and expenses — — — Reductions and write-offs (50 ) (358 ) (177 ) Ending balance $ — $ 50 $ 408

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Activities and Organization	Business Activities and Organization Pfenex Inc. (the Company or Pfenex) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology ® ® ® ® PF708 is a therapeutic equivalent candidate to Forteo, marketed by Eli Lilly and Company. The Company completed enrollment in its Study PF708-301 mid-February Top-line The Company is also developing Px563L/RPA563, novel anthrax vaccine candidates, in response to the United States government’s unmet demand for increased quantity, stability and dose-sparing regimens of anthrax vaccine . In July 2016, Pfenex and Jazz announced an agreement under which Pfenex granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. In addition to the Company’s lead product candidates, its pipeline includes various other biosimilar candidates, including PF582, the Company’s biosimilar candidate to Lucentis ® ® The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
Subsidiary-Pfenex India Development Private Limited ("Pfenex India")	Subsidiary—Pfenex India Development Private Limited (“Pfenex India”) In July 2016, to assist with the continued research and development of its pipeline products, the Company formed a new entity in India. An application for incorporation with the Government of India Ministry of Corporate Affairs was filed and approved for the Company’s subsidiary, Pfenex India Development Private Limited. There has been limited activity in the subsidiary, and all intercompany transactions have been eliminated in the consolidated financial statements. In early 2018, this subsidiary was legally dissolved.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), and reflect all of the Company’s activities, including those of its wholly-owned subsidiary. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These adjustments consist of normal and recurring accruals, as well as non-recurring
Segments	Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. During 2017, 2016 and 2015, substantially all of the Company’s long-lived assets were located within the United States.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
Risk and Uncertainties	Risk and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s products if approved for sale, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals. Products developed by the Company require clearances from international and domestic regulatory agencies prior to commercial sales in such jurisdictions. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. As of December 31, 2017, the Company had an accumulated deficit of $161.7 million and expects to incur substantial operating losses for the next several years. Although the Company believes it has sufficient cash resources to fund all necessary activities leading up to and including submission of an NDA for PF708 to the FDA, the Company may need to obtain additional financing in order to complete clinical studies, launch and commercialize any product candidates for which the Company receives regulatory approval. If Pfenex is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, research and development programs or commercialization efforts. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of six months or less at the time of purchase to be cash equivalents. Cash amounts that are restricted as to withdrawal or usage are presented as restricted cash. In January 2017, the Company entered into a Borrower’s Pledge Agreement with U.S. Bank which required $0.2 million in restricted cash to be provided as security for the Company’s commercial credit card arrangement with this bank.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at three major financial institutions as of December 31, 2017. For the Company’s cash position of $57.9 million as of December 31, 2017, which included restricted cash of $0.2 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance non-performance. Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2017 and 2016, receivables were concentrated among three customers representing 89% of total net receivables for both years. The Company recorded an allowance for doubtful accounts of $0.1 million at December 31, 2016. No allowance for doubtful accounts was recorded at December 31, 2017. For the year ended December 31, 2017, revenue was concentrated among two customers and/or collaboration partners representing 94% of total revenues. Revenue from one collaboration partner represented 80% of total revenue for the year ended December 31, 2016. Two customers and/or collaboration partners represented 70% of total revenue for the year ended December 31, 2015. A portion of revenue is earned from sales outside the United States. Non-U.S. non-U.S. Years Ended December 31, 2017 2016 2015 (in thousands) US Revenue $ 6,477 $ 54,641 $ 8,399 Non-US 22,303 5,553 1,184 $ 28,780 $ 60,194 $ 9,583 During the year ended December 31, 2017, Ireland accounted for more than 10% of the Company’s revenue. For the years ended December 31, 2016 and 2015, no single foreign country accounted for more than 10% of the Company’s revenues.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments, including cash, cash equivalents, restricted cash and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments.
Fair Value Measurements	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: • Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at December 31, 2017 and December 31, 2016 included the Company’s cash and cash equivalents. There were no Level 1 liabilities; • Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at December 31, 2017 or December 31, 2016; and • Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at December 31, 2017 or December 31, 2016.
Accounts and Unbilled Receivables	Accounts and Unbilled Receivables Accounts receivable represent primarily commercial receivables associated with the Company’s service fees, license fees, product sales and receivables from U.S. government contracts. Accounts receivable amounted to $1.1 million and $1.9 million as of December 31, 2017 and 2016, respectively. Unbilled receivables represent reimbursable costs in excess of billings and, where applicable, accrued profit related to long-term government contracts for which revenue has been recognized, but the customer has not yet been billed. Unbilled receivables amounted to $0.2 million and $1.0 million as of December 31, 2017 and 2016, respectively. The Company evaluates the collectability of its receivables based on a variety of factors, including the length of time the receivables are past due, the financial health of its customers and historical experience. Based upon the review of these factors, the Company recorded no allowance for doubtful accounts at December 31, 2017 and $0.1 million at December 31, 2016.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from five to ten years with the exception of leasehold improvements which are amortized over the shorter of the lease term or their estimated useful life.
Intangible Assets	Intangible Assets Intangible assets include customer relationships, developed technology and trade names related to the Company’s asset acquisition and have been capitalized and amortized over the estimated useful life of 15 years, 20 years and 15 years, respectively.
Impairment of Long-Lived Assets Other Than Goodwill	Impairment of Long-Lived Assets Other Than Goodwill The Company assesses potential impairments to its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flow expected to result from the use of the assets. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset. No impairment was noted as of the years ended December 31, 2017 or 2016.
Goodwill	Goodwill Goodwill is the excess of purchase price over the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed, in a business combination. The Company does not amortize goodwill. Instead, goodwill is tested for impairment annually and between annual tests if the Company becomes aware of an event or a change in circumstances that would indicate the carrying amount may be impaired. The Company performs its annual impairment testing as of December 31 st two-step
Preclinical and Clinical Trial Accruals	Preclinical and Clinical Trial Accruals The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on the Company’s behalf. The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of series or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses until the services are rendered.
Revenue	Revenue The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, license agreements, government contracts and sales of reagent protein products, which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 6—Significant Research and Development Agreements. The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case Upfront, nonrefundable licensing payments are assessed to determine whether or not the licensee is able to obtain standalone value from the license. Where the license does not have standalone value, non-refundable Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed. Revenue under service agreements are recorded as services are performed. These agreements do not require development achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement. The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. For the year ended December 31, 2017, revenue was recognized in connection with the achievement of development milestones associated with the Jazz collaboration. The Company recognized $1.0 million and $0.8 million in connection with the achievement of certain milestones for the years ended December 31, 2017 and 2016, respectively. The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of December 31, 2017 and 2016, the Company has had minimal product returns related to reagent protein product sales. No reserve for warranty and return rights was recorded as of December 31, 2017 and 2016. Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user
Cost of Revenue	Cost of Revenue Cost of revenue includes costs incurred in connection with the execution of service contracts. These are primarily reimbursable costs under the Company’s government contracts and include costs for third-party manufacturing, materials and internal labor. Costs related to government contract activities are generally recognized as incurred. Cost of revenue also includes costs to manufacture or purchase, package and ship the Company’s reagent products; these costs are recognized upon shipment to the customer.
Research and Development Expenses	Research and Development Expenses Research and development expenses are recognized as incurred and amounted to $31.9 million, $32.4 million and $18.2 million for the years ending December 31, 2017, 2016 and 2015, respectively.
Stock-Based Compensation	Stock-Based Compensation Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of estimated forfeitures, over the requisite service period. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. The Company estimates the fair value of stock options and other equity-based compensation using a Black-Scholes option pricing model on the date of grant. The Black-Scholes valuation model requires multiple subjective inputs, which are discussed further in Note 8 — Stock-Based Compensation. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally four years; however, certain provisions in the Company’s equity compensation plan provides for shorter and longer vesting periods under certain circumstances.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner
Income Taxes	Income Taxes The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future tax benefit, if any, to be derived from tax credits and loss carryforwards. Deferred income tax expense or benefit would represent the net change during the year in the deferred income tax asset or liability. Deferred tax assets, if any, are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Net (Loss) Income per Share of Common Stock	Net (Loss) Income per Share of Common Stock Basic net (loss) income per common share is calculated by dividing the net (loss) income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding and potentially dilutive securities during the period under the treasury stock method. For purposes of the diluted net (loss) income per share calculation, stock options and employee purchase plan shares are considered to be potentially dilutive securities. Securities are excluded from the computation of diluted net (loss) income per share if their effect would be anti-dilutive to earnings per share. Because the Company has reported a net loss for the years ended December 31, 2017 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. There were no accumulated dividends related to preferred stock at December 31, 2017, 2016 or 2015. Immediately prior to the IPO, the Company issued shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09 In February 2016, the FASB issued ASU No. 2016-02 In November 2016, the FASB issued ASU 2016-18, beginning-of-period end-of-period beginning-of-period end-of-period In January 2017, the FASB issued ASU No. 2017-04, two-step In May 2017, the FASB issued ASU 2017-09, 2017-09

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Sales Revenue	A portion of revenue is earned from sales outside the United States. Non-U.S. non-U.S. Years Ended December 31, 2017 2016 2015 (in thousands) US Revenue $ 6,477 $ 54,641 $ 8,399 Non-US 22,303 5,553 1,184 $ 28,780 $ 60,194 $ 9,583

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of December 31, 2017 and 2016, were determined using the inputs described above and are as follows: Total Fair Value Measurements at Reporting Quoted Prices Significant Significant (in thousands) December 31, 2017 Cash and money market funds $ 57,864 $ 57,864 $ — $ — Total assets measured at fair value $ 57,864 $ 57,864 $ — $ — December 31, 2016 Cash and money market funds $ 81,501 $ 81,501 $ — $ — Total assets measured at fair value $ 81,501 $ 81,501 $ — $ —

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following: December 31, 2017 2016 (in thousands) Furniture and equipment $ 355 $ 350 Computers and IT equipment 368 290 Purchased software 931 869 Lab and research equipment 8,131 5,022 Leasehold improvements 865 739 Construction-in-progress 162 575 Other fixed assets 64 64 Total property and equipment, gross 10,876 7,909 Less: accumulated depreciation and amortization (3,479 ) (2,663 ) Property and equipment, net $ 7,397 $ 5,246 Total property and equipment assets under capital lease were $1.1 million and $0.2 million as of December 31, 2017 and 2016. Accumulated depreciation related to assets under capital lease as of these dates were $94 thousand and $40 thousand, respectively. For the years ended December 31, 2017, 2016 and 2015, total depreciation and amortization expense was $0.9 million, $0.7 million and $0.5 million, respectively, and is included in selling, general and administrative expenses and research and development in the accompanying consolidated statements of operations as follows: Years ended December 31, 2017 2016 2015 (in thousands) Selling, general and administrative $ 327 $ 254 $ 267 Research and development 549 416 274 Total depreciation and amortization expense $ 876 $ 670 $ 541

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets consisted of the following: December 31, 2017 2016 (in thousands) Customer relationships $ 3,750 $ 3,750 Developed technology 4,400 4,400 Trade names 910 910 Gross intangible assets 9,060 9,060 Less: Accumulated amortization (4,289 ) (3,759 ) Total intangible assets, net $ 4,771 $ 5,301

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Components of Accrued Liabilities	Accrued liabilities consisted of the following: December 31, 2017 2016 (in thousands) Accrued vacation $ 477 $ 553 Deferred rent 620 627 Accrued bonuses 1,672 1,385 Other accrued employee-related liabilities 462 293 Accrued professional fees 575 266 Accrued supplier liability 690 428 Accrued subcontractor costs 2,681 4,901 Accrued clinical trial costs 866 73 Other accrued liabilities 870 832 Total accrued liabilities $ 8,913 $ 9,358

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Rent Expense	Rent expense was $0.7 million, $0.7 million, and $0.5 million for the years ended December 31, 2017, 2016 and 2015, respectively, which is included in selling, general and administrative and research and development expenses in the accompanying consolidated statements of operations as follows: Years Ended December 31, 2017 2016 2015 (in thousands) Selling, general and administrative $ 407 $ 375 $ 290 Research and development 326 364 248 Total rent expense $ 733 $ 739 $ 538
Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease	As of December 31, 2017, the total estimated future annual minimum lease payment obligations under the Company’s non-cancelable Payment Amounts Operating Capital Total (in thousands) 2018 $ 984 $ 260 $ 1,244 2019 884 260 1,144 2020 891 199 1,090 2021 908 1 909 2022 and thereafter 2,140 — 2,140 Total future minimum lease payments $ 5,807 $ 720 $ 6,527

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense: Years Ended December 31, 2017 2016 2015 (in thousands) Cost of revenues $ 265 $ 225 $ 124 Research and development 1,028 822 371 Selling, general and administrative 1,830 2,109 1,345 Total $ 3,123 $ 3,156 $ 1,840 2017 2016 2015 (in thousands) Stock-based compensation from: Stock options $ 2,993 $ 2,983 $ 1,761 Employee stock purchase plan 130 173 79 Total $ 3,123 $ 3,156 $ 1,840
Assumptions used to Estimate Fair Value of Stock Options	The following assumptions were used to estimate the fair value of stock options: Years Ended December 31, 2017 2016 2015 Risk-free interest rate 1.5 – 2.4% 1.1 – 2.0% 1.3 – 1.9% Expected volatility 64.0 – 68.0% 63.1 – 68.6% 49.8 – 68.2% Expected dividend yield 0.0% 0.0% 0.0% Expected life of options in years 2.2 - 9.3 5.1 - 6.3 6.0
Stock Option Transactions under 2009, 2014 and 2016 Plans	Stock option transactions under the 2009, 2014 and 2016 Plans during the year ended December 31, 2017 were as follows: Number of Weighted Weighted Aggregate Outstanding at January 1, 2017 2,571 $ 8.62 Granted 1,583 6.51 Exercised (85 ) 0.31 Cancelled (forfeited) (832 ) 9.81 Outstanding at December 31, 2017 3,237 $ 7.50 7.40 $ 392 Vested and expected to vest at December 31, 2017 2,921 $ 7.64 7.21 $ 392 Vested and exercisable at December 31, 2017 1,512 $ 8.44 5.91 $ 392

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of Income Tax (Benefit) Expense	The components of the income tax (benefit) expense are as follows: Years Ended December 31, 2017 2016 2015 (in thousands) Current $ (172 ) $ (2,164 ) $ (680 ) Deferred — 1,955 1,132 Total (benefit) expense $ (172 ) $ (209 ) $ 452
Components of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2017 and 2016 are shown below. A valuation allowance of $19.2 million and $14.5 million for the years ended December 31, 2017 and 2016, respectively, has been established to offset deferred tax assets as realization of such assets is uncertain. December 31, 2017 2016 (in thousands) Deferred tax assets Net operating losses $ 10,968 $ 7,442 Stock-based compensation 1,196 1,069 Research and development credits 5,473 3,456 Deferred revenue 2,581 4,166 Accruals and other 696 846 Total deferred tax assets 20,914 16,979 Deferred tax liabilities Depreciation and amortization (436 ) (629 ) Intangible assets (1,267 ) (1,867 ) Total deferred tax liabilities (1,703 ) (2,496 ) Valuation allowance (19,211 ) (14,483 ) Net deferred tax asset $ — $ —
Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate	A reconciliation of the Company’s effective tax rate and federal statutory tax rate at December 31, 2017, 2016 and 2015 is as follows: December 31, 2017 2016 2015 (in thousands) Federal income taxes $ (8,791 ) $ 1,792 $ (9,440 ) State income taxes (949 ) 190 (673 ) State rate changes (392 ) (1,080 ) 743 Impact of change in federal income tax rates 6,401 — — Stock-based compensation 623 489 (117 ) Valuation allowance 4,728 130 9,984 Research and development credits (1,897 ) (1,683 ) (815 ) Permanent items and other 105 (47 ) 770 Total income tax (benefit) expense $ (172 ) $ (209 ) $ 452
Reconciliation of Unrecognized Tax Benefit activity Excluding Interest and Penalties	Following is a tabular reconciliation of the Company’s Unrecognized Tax Benefits activity (excluding interest and penalties): December 31, 2017 2016 2015 (in thousands) Beginning balance of unrecognized tax benefits $ 730 $ 301 $ — Additions based on tax positions related to the current year 361 369 162 Additions based on tax positions of prior years — 79 139 Reductions for tax positions of prior years (59 ) (19 ) — Ending balance of unrecognized tax benefits $ 1,032 $ 730 $ 301

Net (Loss) Income Per Share o30

Net (Loss) Income Per Share of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table summarizes the computation of basic and diluted net (loss) income per share attributable to common stockholders of the Company: December 31, 2017 2016 2015 (in thousands, except per share data) Net (loss) income $ (25,684 ) $ 5,481 $ (28,216 ) Weighted average shares used to compute basic net (loss) income per share 23,503 23,389 22,376 Dilutive effect of employee stock option plans — 299 — Dilutive weighted-average common shares outstanding 23,503 23,688 22,376 Basic and diluted net (loss) income per common share $ (1.09 ) $ 0.23 $ (1.26 )
Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding	The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding because of their anti-dilutive impact to earnings per share: December 31, 2017 2016 2015 (in thousands) Options to purchase common stock 3,237 1,774 1,638 ESPP 75 60 33

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Data	The following is a summary of the quarterly results of the Company for the years ended December 31, 2017 and 2016: First Second Third Fourth Year Ended (in thousands, except for per share data) 2017 Revenues $ 2,818 $ 3,029 $ 5,024 $ 17,909 $ 28,780 Cost of revenues 810 905 1,766 1,675 5,156 Gross profit 2,008 2,124 3,258 16,234 23,624 Operating expenses 12,084 14,486 12,111 10,918 49,599 Other income, net 44 38 35 2 119 Income tax benefit — — — 172 172 Net (loss) income (10,032 ) (12,324 ) (8,818 ) 5,490 (25,684 ) Net (loss) income per share, basic and diluted $ (0.43 ) $ (0.52 ) $ (0.37 ) $ 0.23 $ (1.09 ) Shares used in the calculation of net (loss) income per share: Basic 23,436 23,486 23,539 23,548 23,503 Diluted 23,436 23,486 23,539 23,697 23,503 2016 Revenues $ 2,764 $ 3,135 $ 48,824 $ 5,471 $ 60,194 Cost of revenues 1,276 1,440 1,285 1,312 5,313 Gross profit 1,488 1,695 47,539 4,159 54,881 Operating expenses 9,696 11,907 13,095 15,060 49,758 Other income, net — 46 52 51 149 Income tax benefit (expense) (1 ) — — 210 209 Net income (loss) (8,209 ) (10,166 ) 34,496 (10,640 ) 5,481 Net income (loss) per share: Basic $ (0.35 ) $ (0.43 ) $ 1.47 $ (0.45 ) $ 0.23 Diluted $ (0.35 ) $ (0.43 ) $ 1.46 $ (0.45 ) $ 0.23 Shares used in the calculation of net income (loss) per share: Basic 23,353 23,379 23,400 23,424 23,389 Diluted 23,353 23,379 23,689 23,424 23,688

Organization and Summary of S32

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Jan. 31, 2017USD ($)Option	Dec. 31, 2017USD ($)CustomerSegments	Dec. 31, 2016USD ($)CountryCustomer	Dec. 31, 2015USD ($)CountryCustomer	Dec. 31, 2010USD ($)
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | Segments		1
Accumulated deficit		$ (161,707,000)	$ (136,023,000)
Cash and cash equivalents original maturity, description		Six months or less
Restricted cash collateral	$ 200,000
Restricted cash		$ 200,000
Allowance for doubtful accounts receivable		0	100,000
Accounts receivable		1,100,000	1,900,000
Unbilled receivables		200,000	1,000,000
Impairment of long-lived assets		0	0
Impairment of goodwill		0	0
Revenue recognized		$ 1,000,000	800,000
Product return policy period		30 days
Research and development expenses		$ 31,925,000	32,418,000	$ 18,183,000
Requisite service period award		4 years
Accumulated dividends related to preferred stock		$ 0	0	$ 0
Jazz Pharmaceuticals Ireland Limited [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Collaboration agreement potential payments		224.5
Revenue recognized		10,100,000	12,100,000
Reagent Protein Product [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warranty reserve accrual		0	$ 0
Novel Anthrax Vaccine Candidate [Member] | Biomedical Advanced Research and Development Authority [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Contractual amount					$ 25,200,000
Number of options period exercised | Option	2
Credit Availability Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Cash		57,900,000
Restricted cash		$ 200,000
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration risk number | Country			0	0
Customer Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for receivables | Customer		3	3
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		94.00%	80.00%	70.00%
Number of customers accounted for revenue | Customer		2	1	2
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		89.00%	89.00%
Trade Names [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		15 years
Customer Relationships [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		15 years
Developed Technology [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		20 years
Maximum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives		10 years
Maximum [Member] | Novel Anthrax Vaccine Candidate [Member] | Biomedical Advanced Research and Development Authority [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Advanced payment received on contracts performed				$ 143,500,000
Minimum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives		5 years
Ireland [Member] | Maximum [Member] | Geographic Concentration Risk [Member] | Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		10.00%

Organization and Summary of S33

Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Concentration Risk [Line Items]
Revenue	$ 17,909	$ 5,024	$ 3,029	$ 2,818	$ 5,471	$ 48,824	$ 3,135	$ 2,764	$ 28,780	$ 60,194	$ 9,583
Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue									28,780	60,194	9,583
Geographic Concentration Risk [Member] | US [Member]
Concentration Risk [Line Items]
Revenue									6,477	54,641	8,399
Geographic Concentration Risk [Member] | Non - US [Member]
Concentration Risk [Line Items]
Revenue									$ 22,303	$ 5,553	$ 1,184

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	$ 57,864	$ 81,501
Total assets measured at fair value	57,864	81,501
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	57,864	81,501
Total assets measured at fair value	$ 57,864	$ 81,501

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 10,876	$ 7,909
Less: accumulated depreciation and amortization	(3,479)	(2,663)
Property and equipment, net	7,397	5,246
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	355	350
Computer and IT Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	368	290
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	931	869
Lab and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	8,131	5,022
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	865	739
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	162	575
Other Fixed Assets [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 64	$ 64

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment assets under capital lease	$ 1,100	$ 200
Accumulated depreciation related to assets under capital lease	94	40
Total depreciation and amortization expense	$ 876	$ 670	$ 541

Property and Equipment - Deprec

Property and Equipment - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$ 876	$ 670	$ 541
Selling, General and Administrative [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	327	254	267
Research and Development [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$ 549	$ 416	$ 274

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$ 9,060	$ 9,060
Less: Accumulated amortization	(4,289)	(3,759)
Total intangible assets, net	4,771	5,301
Trade Names [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	910	910
Customer Relationships [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	3,750	3,750
Developed Technology [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$ 4,400	$ 4,400

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 530	$ 531	$ 531
Estimated amortization expense of intangible assets	500
Selling, General and Administrative [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 500	$ 500	$ 500

Accrued Liabilities - Component

Accrued Liabilities - Components of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Accrued vacation	$ 477	$ 553
Deferred rent	620	627
Accrued bonuses	1,672	1,385
Other accrued employee-related liabilities	462	293
Accrued professional fees	575	266
Accrued supplier liability	690	428
Accrued subcontractor costs	2,681	4,901
Accrued clinical trial costs	866	73
Other accrued liabilities	870	832
Total accrued liabilities	$ 8,913	$ 9,358

Significant Research and Deve41

Significant Research and Development Agreements - Additional Information (Detail) $ in Millions

Jan. 01, 2018

Aug. 31, 2017USD ($)

Jan. 31, 2017USD ($)Option

Jul. 31, 2016USD ($)

Aug. 31, 2015USD ($)Option

Dec. 31, 2014USD ($)

Sep. 30, 2012USD ($)Option

Dec. 31, 2017USD ($)

Mar. 31, 2017

Dec. 31, 2017USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

May 31, 2016USD ($)

Mar. 31, 2015USD ($)

Jan. 31, 2015USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Deferred revenue recognized

$ 1

$ 0.8

Revenue recognized

1

0.8

Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront and option payment

$ 15

Upfront payment

5

Payments of development achievement

$ 13.5

Revenue recognized

14.3

21.6

3.6

Upfront and milestone payment total

18.5

Upfront payment recognized for development services

0.8

Deferred upfront payments

$ 4.2

Estimated selling price determination method

The estimated selling price for the Pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors.

Deferred revenue recognized

$ 10.1

12.1

Revenue recognized

10.1

12.1

Collaborative Arrangements, Product PF582 [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

License revenue recognized

48

$ 3

Collaborative Arrangements, Product PF582 [Member] | Pfizer Collaboration Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Deferred revenue recognized

$ 45.8

Revenue recognized

$ 45.8

Research and Development, Regulatory and Sales Related Milestones [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional payment

189.3

Research and Development Milestones [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment

5

Milestone payments

30.3

Regulatory Milestones [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments

34

Sales Milestones [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments

125

Non-sales-related Milestones [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments

64.3

Substantive Non Sales Related Milestone [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments

30.3

Minimum [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period

15 months

15 months

Minimum [Member] | Jazz Pharmaceuticals Ireland Limited [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period

15 months

Maximum [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period

32 months

35 months

Maximum [Member] | Jazz Pharmaceuticals Ireland Limited [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period

18 months

Up-front Payment Arrangement [Member] | Collaborative Arrangements, Product PF582 [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Non-refundable upfront payment received

$ 51

Pegaspargase Product [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognition, selling price

10

Hematology Product [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognition, selling price

2.5

Remaining upfront payment

$ 4.2

$ 4.2

4.2

Oncology Product [Member] | Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognition, selling price

$ 2.5

Funding Agreements [Member] | U.S. Department of Health and Human Services [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract

$ 143.5

$ 25.2

Base program period

30 months

Number of follow on options | Option

8

Agreement description

The BARDA Advanced Development Agreement is a cost plus fixed fee development contract valued at up to approximately $143.5 million, including a 30 month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. In addition to the base period, BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L/RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019. Each additional option period, if exercised, would extend the period of performance, and the entire contract period of performance would end in August 2020. Subject to continued funding from BARDA, we expect to continue to advance the program with the potential to initiate a Phase 2 trial in 2019.

Revenue of services performed

$ 5.5

5

3.7

Reimbursable costs

$ 3.5

3.9

2.9

Agreement termination description

This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience, or request the Company to stop all or any part of the work for a period of at least 90 days.

Funding Agreements [Member] | U.S. Department of Health and Human Services [Member] | Base Period Performance Contracts [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract

$ 4.9

$ 15.9

Number of follow on options | Option

2

Funding Agreements [Member] | U.S. Department of Health and Human Services [Member] | Option Period Contracts [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract

$ 127.6

Funding Agreements [Member] | National Institute of Allergy and Infectious Diseases [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract

$ 22.9

Base program period

14 months

Number of follow on options | Option

13

Revenue of services performed

$ 0.3

0.5

0.9

Reimbursable costs

$ 0.3

$ 0.4

$ 0.5

Amount of contract eligible for payment

$ 2.2

$ 4.1

$ 3

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended				12 Months Ended
	Jan. 31, 2017	Nov. 30, 2015USD ($)ft²	Sep. 30, 2014USD ($)ft²	Jun. 30, 2010	Dec. 31, 2017USD ($)Claims	Dec. 31, 2016USD ($)Claims	Dec. 31, 2015USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial term of lease				10 years
Lease commencement date					2011-04
Description of lease agreement terms					Under the terms of the Lease, the Company pays annual base rent, subject to an annual fixed percentage increase, plus its share of common operating expenses and tax obligations.
Annual base rent abatement percentage					50.00%
Extend term of lease					Lease to extend the term for an additional three years through March 31, 2024
Lease to add facilities | ft²		16,811	7,315
Increase in estimated rent payments over life of lease		$ 2,300
Additional term of lease agreement			3 years
Operating lease expiration date					Mar. 31, 2024
Rent expense					$ 733	$ 739	$ 538
Total contract costs					6,527
Research and Development Arrangements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total contract costs					25,900
Research and development costs incurred					$ 15,900
Indemnification Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of material legal proceedings | Claims					0	0
Sublease Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sublease agreement term	8 months
Office and Lab Equipment [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Operating and capital lease expiration dates					Various dates through December 2021.
New Space [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase in estimated rent payments over life of lease			$ 1,500
Existing Space [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase in estimated rent payments over life of lease			$ 1,400

Commitments and Contingencies43

Commitments and Contingencies - Schedule of Rent Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Lease Rent Expense [Line Items]
Total rent expense	$ 733	$ 739	$ 538
Selling, General and Administrative [Member]
Schedule of Lease Rent Expense [Line Items]
Total rent expense	407	375	290
Research and Development [Member]
Schedule of Lease Rent Expense [Line Items]
Total rent expense	$ 326	$ 364	$ 248

Commitments and Contingencies44

Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2018	$ 984
Operating Leases, 2019	884
Operating Leases, 2020	891
Operating Leases, 2021	908
Operating Leases, 2022 and thereafter	2,140
Operating Leases, Total future minimum lease payments	5,807
Capital Leases, 2018	260
Capital Leases, 2019	260
Capital Leases, 2020	199
Capital Leases, 2021	1
Capital Leases, 2022 and thereafter	0
Capital Leases, Total future minimum lease payments	720
Total future minimum lease payments, 2018	1,244
Total future minimum lease payments, 2019	1,144
Total future minimum lease payments, 2020	1,090
Total future minimum lease payments, 2021	909
Total future minimum lease payments, 2022 and thereafter	2,140
Total future minimum lease payments	$ 6,527

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 3,123	$ 3,156	$ 1,840
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	265	225	124
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	1,028	822	371
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	1,830	2,109	1,345
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	2,993	2,983	1,761
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 130	$ 173	$ 79

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	1,583,000
Shares reserved for issuance	1,270,388
Number of common stock outstanding	3,237,000	2,571,000
Weighted average remaining contractual term	7 years 4 months 24 days
Shares annual increase terms under ESPP	Annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator
Annually shares increase percent under ESPP					1.50%
Annual increase in number of shares available for sale under ESPP	355,618
Common stock issued in connection with payment of dividends	1,217,784
Weighted average grant date fair value, granted	$ 2.92	$ 5.47	$ 5.91
Fair value of shares vested during the period	$ 3,900	$ 972,000	$ 971,000
Unrecognized compensation cost related to unvested stock options	$ 4,300,000
Unrecognized compensation cost related to unvested stock options, weighted average period for recognition	2 years 6 months 14 days
Aggregate intrinsic value, excess of exercise price over estimated fair value of options exercised	$ 300,000	$ 600,000	$ 4,700,000
2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	0
Shares reserved for issuance	1,100,000
Number of common stock outstanding	400,000
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	2.4			3.1
Stockholders' equity, increase	$ 2,500,000
Share based plan ten years date of grant	Stock options granted to date under the 2009 Plan and the 2014 Plan have a term of ten years from the date of grant
2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock outstanding	400,000
Weighted average remaining contractual term	4 years
Share based plan ten years date of grant	Stock options granted under the 2016 Plan have a term of ten years from the date of grant
Percentage of share based compensation fair value	100.00%
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
Common stock available for issuance	100,000
2009 and 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	10 years
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased under ESPP	92,493
Incentive Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	5 years
Percentage of voting power	10.00%
Common Stock [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock outstanding	2,400,000
Maximum [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	5,500,000
Maximum [Member] | 2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	500,000
Maximum [Member] | Scenario, May be added to the 2014 Plan [Member] | 2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of previously granted shares that can be added	961,755

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions used to Estimate Fair Value of Stock Options (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.50%	1.10%	1.30%
Risk-free interest rate, maximum	2.40%	2.00%	1.90%
Expected volatility, minimum	64.00%	63.10%	49.80%
Expected volatility, maximum	68.00%	68.60%	68.20%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of options in years			6 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	2 years 2 months 12 days	5 years 1 month 6 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	9 years 3 months 19 days	6 years 3 months 19 days

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Transactions under 2009, 2014 and 2016 Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Options, beginning balance | shares	2,571
Number of Options, Granted | shares	1,583
Number of Options, Exercised | shares	(85)
Number of Options, Cancelled (forfeited) | shares	(832)
Number of Options, ending balance | shares	3,237
Number of Options, Vested and expected to vest at December 31, 2017 | shares	2,921
Number of Options, Vested and exercisable at December 31, 2017 | shares	1,512
Weighted Average Exercise Price, Outstanding, beginning balance | $ / shares	$ 8.62
Weighted Average Exercise Price, Granted | $ / shares	6.51
Weighted Average Exercise Price, Exercised | $ / shares	0.31
Weighted Average Exercise Price, Cancelled (forfeited) | $ / shares	9.81
Weighted Average Exercise Price, Outstanding, ending balance | $ / shares	7.50
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2017 | $ / shares	7.64
Weighted Average Exercise Price, Vested and exercisable at December 31, 2017 | $ / shares	$ 8.44
Weighted Average Remaining Contractual Term (in years), Outstanding	7 years 4 months 24 days
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest at December 31, 2017	7 years 2 months 16 days
Weighted Average Remaining Contractual Term (in years), Vested and exercisable at December 31, 2017	5 years 10 months 28 days
Aggregate Intrinsic Value, Outstanding | $	$ 392
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2017 | $	392
Aggregate Intrinsic Value, Vested and exercisable at December 31, 2017 | $	$ 392

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan [Abstract]
Employer Matching Contributions to the 401(K), Amount	$ 226,000	$ 197,000	$ 0

Income Taxes - Components of In

Income Taxes - Components of Income Tax (Benefit) Expense (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current				$ (172)	$ (2,164)	$ (680)
Deferred					1,955	1,132
Total (benefit) expense	$ (172)	$ (210)	$ 1	$ (172)	$ (209)	$ 452

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Contingency [Line Items]
Federal corporate tax rate		35.00%
Tax Cuts and Jobs Act, incomplete accounting, provisional income tax expense (benefit)		$ 6,400,000
Provision for federal alternative minimum tax		$ 200,000
Federal research and development tax credit expiration year		2,030
Operating loss carryforwards, expiration year		2,037
Valuation allowance		$ 19,211,000	$ 14,483,000
Uncertain tax positions		50.00%
Effective tax rate recognized		$ 900,000
Accrued interest or penalties		0	0
Interest or penalties expense		$ 0	$ 0	$ 0
Expected Tax Expenses [Member]
Income Tax Contingency [Line Items]
Federal corporate tax rate	21.00%
Tax Year 2015 [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax years from and including remain open for examination		2,015
Tax Year 2016 [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax years from and including remain open for examination		2,016
State [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards		$ 25,900,000
State [Member] | Research and Development Credits [Member]
Income Tax Contingency [Line Items]
Research and development tax credits carryforward		$ 2,700,000
State [Member] | Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years from and including remain open for examination		2,009
Federal [Member]
Income Tax Contingency [Line Items]
Operating loss carryforwards		$ 43,600,000
Federal [Member] | Research and Development Credits [Member]
Income Tax Contingency [Line Items]
Research and development tax credits carryforward		$ 4,100,000
Federal research and development tax credit expiration period		20 years

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets
Net operating losses	$ 10,968	$ 7,442
Stock-based compensation	1,196	1,069
Research and development credits	5,473	3,456
Deferred revenue	2,581	4,166
Accruals and other	696	846
Total deferred tax assets	20,914	16,979
Deferred tax liabilities
Depreciation and amortization	(436)	(629)
Intangible assets	(1,267)	(1,867)
Total deferred tax liabilities	(1,703)	(2,496)
Valuation allowance	(19,211)	(14,483)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal income taxes				$ (8,791)	$ 1,792	$ (9,440)
State income taxes				(949)	190	(673)
State rate changes				(392)	(1,080)	743
Impact of change in federal income tax rates				6,401
Stock-based compensation				623	489	(117)
Valuation allowance				4,728	130	9,984
Research and development credits				(1,897)	(1,683)	(815)
Permanent items and other				105	(47)	770
Total (benefit) expense	$ (172)	$ (210)	$ 1	$ (172)	$ (209)	$ 452

Income Taxes - Reconciliation54

Income Taxes - Reconciliation of Unrecognized Tax Benefit activity Excluding Interest and Penalties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance of unrecognized tax benefits	$ 730	$ 301
Additions based on tax positions related to the current year	361	369	$ 162
Additions based on tax positions of prior years		79	139
Reductions for tax positions of prior years	(59)	(19)
Ending balance of unrecognized tax benefits	$ 1,032	$ 730	$ 301

Net (Loss) Income Per Share o55

Net (Loss) Income Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net (loss) income	$ 5,490	$ (8,818)	$ (12,324)	$ (10,032)	$ (10,640)	$ 34,496	$ (10,166)	$ (8,209)	$ (25,684)	$ 5,481	$ (28,216)
Weighted average shares used to compute basic net (loss) income per share	23,548	23,539	23,486	23,436	23,424	23,400	23,379	23,353	23,503	23,389	22,376
Dilutive effect of employee stock option plans										299
Dilutive weighted-average common shares outstanding	23,697	23,539	23,486	23,436	23,424	23,689	23,379	23,353	23,503	23,688	22,376
Basic and diluted net (loss) income per common share	$ 0.23	$ (0.37)	$ (0.52)	$ (0.43)					$ (1.09)	$ 0.23	$ (1.26)

Net (Loss) Income Per Share o56

Net (Loss) Income Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from the computation of diluted shares	3,237	1,774	1,638
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from the computation of diluted shares	75	60	33

Quarterly Financial Data - Summ

Quarterly Financial Data - Summary of Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 17,909	$ 5,024	$ 3,029	$ 2,818	$ 5,471	$ 48,824	$ 3,135	$ 2,764	$ 28,780	$ 60,194	$ 9,583
Cost of revenues	1,675	1,766	905	810	1,312	1,285	1,440	1,276	5,156	5,313	4,640
Gross profit	16,234	3,258	2,124	2,008	4,159	47,539	1,695	1,488	23,624	54,881	4,943
Operating expenses	10,918	12,111	14,486	12,084	15,060	13,095	11,907	9,696	49,599	49,758	32,781
Other income, net	2	35	38	44	51	52	46		119	149	74
Income tax benefit (expense)	172				210			(1)	172	209	(452)
Net (loss) income	$ 5,490	$ (8,818)	$ (12,324)	$ (10,032)	$ (10,640)	$ 34,496	$ (10,166)	$ (8,209)	$ (25,684)	$ 5,481	$ (28,216)
Net income (loss) per share:
Basic					$ (0.45)	$ 1.47	$ (0.43)	$ (0.35)		$ 0.23
Diluted					$ (0.45)	$ 1.46	$ (0.43)	$ (0.35)		0.23
Net (loss) income per share, basic and diluted	$ 0.23	$ (0.37)	$ (0.52)	$ (0.43)					$ (1.09)	$ 0.23	$ (1.26)
Shares used in the calculation of net (loss) income per share:
Basic	23,548	23,539	23,486	23,436	23,424	23,400	23,379	23,353	23,503	23,389	22,376
Diluted	23,697	23,539	23,486	23,436	23,424	23,689	23,379	23,353	23,503	23,688	22,376

Schedule II - Valuation and Q58

Schedule II - Valuation and Qualifying Accounts (Detail) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 50	$ 408	$ 585
Charged to costs and expenses	0	0	0
Reductions and write-offs	$ (50)	(358)	(177)
Ending balance		$ 50	$ 408